Literature DB >> 9080896

Clinical and histological responses of congenital melanocytic nevi after single treatment with Q-switched lasers.

J M Grevelink1, R L van Leeuwen, R R Anderson, H R Byers.   

Abstract

BACKGROUND: Laser irradiation of congenital melanocytic nevi is a controversial treatment. Recurrence of lesions after laser treatment appears to be the rule, and the effects of laser irradiation on cellular biological behavior and the possible mutagenic responses of nevomelanocytes that have received nonlethal doses of irradiation are still unclear. Without treatment, there is an increased potential for malignant degeneration over a life-time. The purpose of this study was to examine the effects of Q-switched lasers on congenital nevi and to explain the mechanism(s) behind the response of the nevi to laser treatment. Five congenital nevi were divided into 3 equal parts: 1 part was treated with the Q-switched ruby laser at a wavelength of 694 nm, 1 part was treated with the Q-switched neodymium: YAG laser at a wavelength of 1064 nm, and 1 part was left untreated to serve as control. At intervals ranging from 3 days to 3 months after laser irradiation, the lesions were excised and evaluated by routine staining. This clinical study was conducted entirely at the Massachusetts General Hospital Dermatology Laser Center, Boston, Mass. OBSERVATIONS: Both the superficial and the deep portions of the congenital melanocytic nevi were affected by the 2 lasers, as evidenced by macroscopic inspection as well as microscopic evaluation. However, the Q-switched laser treatment did not destroy all nevomelanocytes, particularly in the deeper, less pigmented portions of the lesions.
CONCLUSIONS: Both the Q-switched ruby laser and the neodymium: YAG laser often removed only the superficial portion of the congenital melanocytic nevi. The Q-switched ruby laser (694 nm) appeared to be more effective in removing nevomelanocytes than the Q-switched neodymium: YAG laser (1064 nm).

Entities:  

Mesh:

Year:  1997        PMID: 9080896

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  9 in total

Review 1.  [Medical dermatologic laser therapy. A review].

Authors:  B Greve; C Raulin
Journal:  Hautarzt       Date:  2003-05-23       Impact factor: 0.751

2.  Treatment of Congenital Melanocytic Nevi With a Dual-Wavelengths Copper Vapor Laser: A Case Series.

Authors:  Igor V Ponomarev; Sergey B Topchiy; Alexandra E Pushkareva; Svetlana V Klyuchareva; Yury N Andrusenko
Journal:  J Lasers Med Sci       Date:  2021-02-14

3.  A Combination of Dual-mode 2,940 nm Er:YAG Laser Ablation with Surgical Excision for Treating Medium-sized Congenital Melanocytic Nevus.

Authors:  Ji Yeon Lim; Yun Jeong; Kyu Kwang Whang
Journal:  Ann Dermatol       Date:  2009-05-31       Impact factor: 1.444

4.  Cosmetic light therapies and the risks of atypical pigmented lesions.

Authors:  Lauren Curry; Natalie Cunningham; Shweta Dhawan
Journal:  Can Fam Physician       Date:  2021-06       Impact factor: 3.275

5.  Q-switched Nd:YAG Laser to Treat Nevomelanocytic Nevi.

Authors:  Sg Parasramani; Cm Oberai; Kr Amonkar; S Naik
Journal:  J Cutan Aesthet Surg       Date:  2009-07

6.  Treatment of nasal ala nodular congenital melanocytic naevus with carbon dioxide laser and Q-switched Nd:YAG laser.

Authors:  Ying Zeng; Chenyang Ji; Kui Zhan; Weili Weng
Journal:  Lasers Med Sci       Date:  2016-07-22       Impact factor: 3.161

7.  Laser treatment of congenital melanocytic nevi: a review of the literature.

Authors:  Fleta N Bray; Vidhi Shah; Keyvan Nouri
Journal:  Lasers Med Sci       Date:  2015-11-12       Impact factor: 3.161

8.  Congenital giant nevocellular nevus of the back with deep extension to the fat and fascia.

Authors:  Marcos Ro Jaeger; Ronald M Zuker
Journal:  Can J Plast Surg       Date:  2006

Review 9.  Optimal management of common acquired melanocytic nevi (moles): current perspectives.

Authors:  Kabir Sardana; Payal Chakravarty; Khushbu Goel
Journal:  Clin Cosmet Investig Dermatol       Date:  2014-03-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.